MADRIGAL PHARMACEUTICALS, INC.

The company is a biopharmaceutical enterprise dedicated to developing and commercializing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), an inflammatory liver condition that causes progressive scarring and organ impairment. Its principal commercial offering is Rezdiffra (resmetirom), an oral thyroid hormone receptor beta agonist taken once daily to address liver fat accumulation and fibrosis. In addition, the firm advances a clinical pipeline that includes glucagon-like peptide-1 receptor agonists, diacylglycerol O-acyltransferase 2 inhibitors, and small interfering RNA programs designed to address complementary metabolic and genetic pathways of liver disease. Its treatments target adult patients diagnosed with noncirrhotic MASH who exhibit moderate to advanced liver fibrosis.

Commercial operations are active in the United States and Germany, where the company launched its core pharmaceutical product following regulatory clearances. It is also preparing for broader distribution across member states of the European Union and other international regions through direct filings or third-party distribution partnerships. The provided excerpt does not disclose the location of the corporate headquarters.

Summary of the business section of Madrigal Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 915 full-time employees, including 258 engaged in research, development and medical affairs, 526 in commercial activities and 131 in general and administrative functions.”